MEA Drug modeling software Market - Industry Trends and Forecast to 2030

List of Tables

The drug modeling software market is expected to reach USD 16,808.81 million by 2030 from USD 8,504.35 million in 2022, growing at a CAGR of 9.2% during the forecast period of 2023 to 2033.

Market Segmentation:

Middle East and Africa Drug Modeling Software Market, By Component (Software, and Services), Operating System (Windows, Linux, Mac OS, and Others), Deployment Mode (Cloud Based, Hybrid Based, and On Premises), Enterprise Size(Large Enterprise Size, Small and Medium Enterprise Size), Application (Graphical Molecular Modeling, Gene Sequence Analysis, Protein Modeling, Modeling Crystal Structures, Cheminformatics, High Throughput Virtual Screening, Gas and Solution Phase Reaction, Medical Imaging, and Others), Purchase Model (Subscription Based, and One- Time License), End User( Pharmaceutical and Biotechnology Companies, Contract Research Organization, Research Institutes, Regulatory Authorities, and Others), Country (South Africa , Saudi Arabia , UAE , Egypt, Israel , Oman , Bahrain , Kuwait , Qatar , Rest of Middle East and Africa) - Industry Trends and Forecast to 2030.

Overview of Drug Modeling Software Market Dynamics :

Driver
Rising drug discovery and development activities
Restrain
Lack of quality data base
Opportunity
Cloud computing and big data analytics in drug modelling

Market Players:

The key market players operating in the drug modeling software market are listed below:

Dotmatics
BC Platforms
InSilicoTrials Technologies.
VeriSIM Life., Atomwise Inc.
Certara, USA.
GENECODE
Cresset., and Nanome Inc.
SIMULATIONS PLUS.
Dassault Systemes
Scripps Research
XtalPi Inc.
Xybion
ArgusLab
Schrodinger, Inc.

1 INTRODUCTION 57

1.1 OBJECTIVES OF THE STUDY 57
1.2 MARKET DEFINITION 57
1.3 OVERVIEW OF THE MIDDLE EAST & AFRICA DRUG MODELING SOFTWARE MARKET 57
1.4 CURRENCY AND PRICING 59
1.5 LIMITATIONS 59
1.6 MARKETS COVERED 59

2 MARKET SEGMENTATION 62

2.1 MARKETS COVERED 62
2.2 GEOGRAPHICAL SCOPE 63
2.3 YEARS CONSIDERED FOR THE STUDY 64
2.4 DBMR TRIPOD DATA VALIDATION MODEL 65
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 68
2.6 MULTIVARIATE MODELING 69
2.7 COMPONENT LIFELINE CURVE 69
2.8 DBMR MARKET POSITION GRID 70
2.9 VENDOR SHARE ANALYSIS 71
2.10 MARKET APPLICATION COVERAGE GRID 72
2.11 SECONDARY SOURCES 73
2.12 ASSUMPTIONS 73

3 EXECUTIVE SUMMARY 74

3.1 PORTER'S FIVE FORCES MODEL 78
3.2 VALUE CHAIN ANALYSIS 79
3.3 REGULATORY STANDARDS 80
3.4 TECHNOLOGICAL TRENDS 81
3.5 BENEFITS OF DRUG MODELING SOFTWARE 82

4 MARKET OVERVIEW 83

4.1 DRIVERS 85
- 4.1.1 RISING DRUG DISCOVERY AND DEVELOPMENT ACTIVITIES 85
- 4.1.2 RISING DEMAND FOR NOVEL THERAPIES 87
- 4.1.3 PRECISION MEDICINE AND INTERVENTION OF AI IN DRUG MODELLING 88
4.2 RESTRAINTS 89
- 4.2.1 LACK OF QUALITY DATA BASE 89
- 4.2.2 HIGH COST OF MANUFACTURING OF DRUG MODELLING SOFTWARE 89
4.3 OPPORTUNITIES 90
- 4.3.1 CLOUD COMPUTING AND BIG DATA ANALYTICS IN DRUG MODELLING 90
- 4.3.2 INCREASING ADOPTION OF MODELLING TOOLS IN DRUG DISCOVERY 91
4.4 CHALLENGES 91
- 4.4.1 LACK OF PROCEDURE FOR MULTI-DRUG EFFECT ASSESMENT 91
- 4.4.2 CHALLENGES WITH MODEL INTERPRETATION 92

5 MIDDLE EAST & AFRICA DRUG MODELING SOFTWARE MARKET, BY COMPONENTS 93

5.1 OVERVIEW 94
- 5.1.1 SOFTWARE 97
  - 5.1.1.1 INTEGRATED 98
  - 5.1.1.2 STANDALONE 98
  - 5.1.1.3 LIGAND BASED 98
  - 5.1.1.4 STRUCTURE BASED 98
5.2 SERVICES 98
- 5.2.1 PROFESSIONAL SERVICES 99
  - 5.2.1.1 CONSULTING AND TRAINING 100
  - 5.2.1.2 INTEGRATION AND IMPLEMENTATION 100
  - 5.2.1.3 SUPPORT AND MAINTENANCE 100
- 5.2.2 MANAGED SERVICES 100

6 MIDDLE EAST & AFRICA DRUG MODELING SOFTWARE MARKET, BY OPERATING SYSTEM 101

6.1 OVERVIEW 102
6.2 WINDOWS 105
6.3 LINUX 105
6.4 MAC OS 106
6.5 OTHERS 107

7 MIDDLE EAST & AFRICA DRUG MODELING SOFTWARE MARKET, BY DEPLOYMENT MODE 108

7.1 OVERVIEW 109
7.2 CLOUD BASED 112
7.3 HYBRID-BASED 112
7.4 ON-PREMISES 113

8 MIDDLE EAST & AFRICA DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE 114

8.1 OVERVIEW 115
8.2 LARGE ENTERPRISE SIZE 118
8.3 SMALL & MEDIUM ENTERPRISE SIZE 118

9 MIDDLE EAST & AFRICA DRUG MODELING SOFTWARE MARKET, BY APPLICATION 120

9.1 OVERVIEW 121
9.2 GRAPHICAL MOLECULAR MODELING 124
9.3 GENE SEQUENCE ANALYSIS 124
9.4 PROTEIN MODELING 125
9.5 MODELING CRYSTAL STRUCTURES 126
9.6 CHEMINFORMATICS 127
9.7 HIGH THROUGHPUT VIRTUAL SCREENING 128
9.8 GAS & SOLUTION PHASE REACTION 128
9.9 MEDICAL IMAGING 129
9.10 OTHERS 130

10 MIDDLE EAST & AFRICA DRUG MODELING SOFTWARE MARKET, BY PURCHASING MODEL 131

10.1 OVERVIEW 132
10.2 SUBSCRIPTION BASED 135
- 10.2.1 ANNUALLY SUBSCRIPTION 136
- 10.2.2 MONTHLY SUBSCRIPTION 136
10.3 ONE-TIME LICENSE 136
- 10.3.1 GROUP LICENSE 137
- 10.3.2 DESKTOP LICENSE 137
- 10.3.3 OTHERS 137

11 MIDDLE EAST & AFRICA DRUG MODELING SOFTWARE MARKET, BY END USER 138

11.1 OVERVIEW 139
11.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 142
- 11.2.1 LARGE ENTERPRISE SIZE 143
- 11.2.2 SMALL & MEDIUM ENTERPRISE SIZE 143
11.3 CONTRACT RESEARCH ORGANIZATIONS 143
- 11.3.1 LARGE ENTERPRISE SIZE 144
- 11.3.2 SMALL & MEDIUM ENTERPRISE SIZE 144
11.4 RESEARCH INSTITUTES 144
- 11.4.1 LARGE ENTERPRISE SIZE 145
- 11.4.2 SMALL & MEDIUM ENTERPRISE SIZE 145
11.5 REGULATORY AUTHORITIES 145
- 11.5.1 LARGE ENTERPRISE SIZE 146
- 11.5.2 SMALL & MEDIUM ENTERPRISE SIZE 147
11.6 OTHERS 147
- 11.6.1 LARGE ENTERPRISE SIZE 148
- 11.6.2 SMALL & MEDIUM ENTERPRISE SIZE 148

12 MIDDLE EAST & AFRICA DRUG MODELING SOFTWARE MARKET, BY REGION 149

12.1 MIDDLE EAST AND AFRICA 150
- 12.1.1 SOUTH AFRICA 160
- 12.1.2 SAUDI ARABIA 165
- 12.1.3 U.A.E. 170
- 12.1.4 EGYPT 175
- 12.1.5 ISRAEL 180
- 12.1.6 OMAN 185
- 12.1.7 BAHRAIN 190
- 12.1.8 KUWAIT 195
- 12.1.9 QATAR 200
- 12.1.10 REST OF MIDDLE EAST AND AFRICA 205

13 MIDDLE EAST & AFRICA DRUG MODELING SOFTWARE MARKET: COMPANY LANDSCAPE 206

13.1 COMPANY SHARE ANALYSIS: MIDDLE EAST & AFRICA 206

14 SWOT ANALYSIS 207

15 MIDDLE EAST & AFRICA DRUG MODELING SOFTWARE MARKET, COMPANY PROFILE 208

15.1 DASSAULT SYSTEMES 208
- 15.1.1 COMPANY SNAPSHOT 208
- 15.1.2 REVENUE ANALYSIS 208
- 15.1.3 COMPANY SHARE ANALYSIS 209
- 15.1.4 PRODUCT PORTFOLIO 209
- 15.1.5 RECENT DEVELOPMENT 209
15.2 AMAZON WEB SERVICES, INC. OR ITS AFFILIATES.(A SUBSIDIARY OF AMAZON) 210
- 15.2.1 COMPANY SNAPSHOT 210
- 15.2.2 REVENUE ANALYSIS 210
- 15.2.3 COMPANY SHARE ANALYSIS 211
- 15.2.4 PRODUCT PORTFOLIO 211
- 15.2.5 RECENT DEVELOPMENTS 211
15.3 CERTARA, USA. 212
- 15.3.1 COMPANY SNAPSHOT 212
- 15.3.2 REVENUE ANALYSIS 212
- 15.3.3 COMPANY SHARE ANALYSIS 213
- 15.3.4 PRODUCT PORTFOLIO 213
- 15.3.5 RECENT DEVELOPMENTS 213
15.4 SCHRODINGER, INC. 214
- 15.4.1 COMPANY SNAPSHOT 214
- 15.4.2 REVENUE ANALYSIS 214
- 15.4.3 COMPANY SHARE ANALYSIS 215
- 15.4.4 PRODUCT PORTFOLIO 215
- 15.4.5 RECENT DEVELOPMENT 215
15.5 CRESSET. 216
- 15.5.1 COMPANY SNAPSHOT 216
- 15.5.2 COMPANY SHARE ANALYSIS 216
- 15.5.3 PRODUCT PORTFOLIO 217
- 15.5.4 RECENT DEVELOPMENTS 217
15.6 ACELLERA LTD 218
- 15.6.1 COMPANY SNAPSHOT 218
- 15.6.2 PRODUCT PORTFOLIO 218
- 15.6.3 RECENT DEVELOPMENTS 218
15.7 ARGUSLAB 219
- 15.7.1 COMPANY SNAPSHOT 219
- 15.7.2 PRODUCT PORTFOLIO 219
- 15.7.3 RECENT DEVELOPMENT 219
15.8 ATOMWISE INC. 220
- 15.8.1 COMPANY SNAPSHOT 220
- 15.8.2 PRODUCT PORTFOLIO 220
- 15.8.3 RECENT DEVELOPMENT 220
15.9 BC PLATFORMS 221
- 15.9.1 COMPANY SNAPSHOT 221
- 15.9.2 PRODUCT PORTFOLIO 221
- 15.9.3 RECENT DEVELOPMENTS 222
15.10 BIOSOLVEIT GMBH 223
- 15.10.1 COMPANY SNAPSHOT 223
- 15.10.2 PRODUCT PORTFOLIO 223
- 15.10.3 RECENT DEVELOPMENT 223
15.11 DOTMATICS 224
- 15.11.1 COMPANY SNAPSHOT 224
- 15.11.2 PRODUCT PORTFOLIO 224
- 15.11.3 RECENT DEVELOPMENTS 225
15.12 GENECODE 226
- 15.12.1 COMPANY SNAPSHOT 226
- 15.12.2 PRODUCT PORTFOLIO 226
- 15.12.3 RECENT DEVELOPMENT 226
15.13 INSILICOTRIALS TECHNOLOGIES. 227
- 15.13.1 COMPANY SNAPSHOT 227
- 15.13.2 PRODUCT PORTFOLIO 227
- 15.13.3 RECENT DEVELOPMENTS 228
15.14 NANOME INC. 229
- 15.14.1 COMPANY SNAPSHOT 229
- 15.14.2 PRODUCT PORTFOLIO 229
- 15.14.3 RECENT DEVELOPMENT 229
15.15 OPTIBRIUM, LTD. 230
- 15.15.1 COMPANY SNAPSHOT 230
- 15.15.2 PRODUCT PORTFOLIO 230
- 15.15.3 RECENT DEVELOPMENT 230
15.16 PHARMACELERA 231
- 15.16.1 COMPANY SNAPSHOT 231
- 15.16.2 PRODUCT PORTFOLIO 231
- 15.16.3 RECENT DEVELOPMENT 231
15.17 SIMULATIONS PLUS. 232
- 15.17.1 COMPANY SNAPSHOT 232
- 15.17.2 REVENUE ANALYSIS 233
- 15.17.3 COMPANY SHARE ANALYSIS 234
- 15.17.4 PRODUCT PORTFOLIO 234
- 15.17.5 RECENT DEVELOPMENT 235
15.18 THE SCRIPPS RESEARCH INSTITUTE 236
- 15.18.1 COMPANY SNAPSHOT 236
- 15.18.2 PRODUCT PORTFOLIO 236
- 15.18.3 RECENT DEVELOPMENT 236
15.19 VERISIM LIFE. 237
- 15.19.1 COMPANY SNAPSHOT 237
- 15.19.2 PRODUCT PORTFOLIO 237
- 15.19.3 RECENT DEVELOPMENTS 237
15.20 XTALPI INC. 238
- 15.20.1 COMPANY SNAPSHOT 238
- 15.20.2 PRODUCT PORTFOLIO 238
- 15.20.3 RECENT DEVELOPMENT 238
15.21 XYBION DIGITAL INC. 239
- 15.21.1 COMPANY SNAPSHOT 239
- 15.21.2 REVENUE ANALYSIS 239
- 15.21.3 PRODUCT PORTFOLIO 240
- 15.21.4 RECENT DEVELOPMENT 240

16 QUESTIONNAIRE 241

17 RELATED REPORTS 245

LIST OF TABLES

TABLE 1 MIDDLE EAST & AFRICA DRUG MODELING SOFTWARE MARKET, BY COMPONENTS, 2021-2030 (USD MILLION) 63
TABLE 2 MIDDLE EAST & AFRICA SOFTAWARE IN DRUG MODELING SOFTWARE MARKET, BY REGION, 2021-2030 (USD MILLION) 64
TABLE 3 MIDDLE EAST & AFRICA SOFTWARE IN DRUG MODELING SOFTWARE MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 64
TABLE 4 MIDDLE EAST & AFRICA SOFTWARE IN DRUG MODELING SOFTWARE MARKET, BY TYPE, 2021-2030 (USD MILLION) 65
TABLE 5 MIDDLE EAST & AFRICA SERVICES IN DRUG MODELING SOFTWARE MARKET, BY REGION, 2021-2030 (USD MILLION) 66
TABLE 6 MIDDLE EAST & AFRICA SERVICES IN DRUG MODELING SOFTWARE MARKET, BY TYPE, 2021-2030 (USD MILLION) 66
TABLE 7 MIDDLE EAST & AFRICA PROFESSIONAL SERVICES IN DRUG MODELING SOFTWARE MARKET, BY TYPE, 2021-2030 (USD MILLION) 67
TABLE 8 MIDDLE EAST & AFRICA DRUG MODELING SOFTWARE MARKET, BY OPERATING SYSTEM, 2021-2030 (USD MILLION) 71
TABLE 9 MIDDLE EAST & AFRICA WINDOWS IN DRUG MODELING SOFTWARE MARKET, BY REGION, 2021-2030 (USD MILLION) 72
TABLE 10 MIDDLE EAST & AFRICA LINUX IN DRUG MODELING SOFTWARE MARKET, BY REGION, 2021-2030 (USD MILLION) 73
TABLE 11 MIDDLE EAST & AFRICA MAC OS IN DRUG MODELING SOFTWARE MARKET, BY REGION, 2021-2030 (USD MILLION) 73
TABLE 12 MIDDLE EAST & AFRICA OTHERS IN DRUG MODELING SOFTWARE MARKET, BY REGION, 2021-2030 (USD MILLION) 74
TABLE 13 MIDDLE EAST & AFRICA DRUG MODELING SOFTWARE MARKET, BY DEPLOYMENT MODE, 2021-2030 (USD MILLION) 78
TABLE 14 MIDDLE EAST & AFRICA CLOUD BASED IN DRUG MODELING SOFTWARE MARKET, BY REGION, 2021-2030 (USD MILLION) 79
TABLE 15 MIDDLE EAST & AFRICA HYBRID-BASED IN DRUG MODELING SOFTWARE MARKET, BY REGION, 2021-2030 (USD MILLION) 80
TABLE 16 MIDDLE EAST & AFRICA ON-PREMISES IN DRUG MODELING SOFTWARE MARKET, BY REGION, 2021-2030 (USD MILLION) 80
TABLE 17 MIDDLE EAST & AFRICA DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 84
TABLE 18 MIDDLE EAST & AFRICA LARGE ENTERPRISE SIZE IN DRUG MODELING SOFTWARE MARKET, BY REGION, 2021-2030 (USD MILLION) 85
TABLE 19 MIDDLE EAST & AFRICA SMALL & MEDIUM ENTERPRISE SIZE IN DRUG MODELING SOFTWARE MARKET, BY REGION, 2021-2030 (USD MILLION) 86
TABLE 20 MIDDLE EAST & AFRICA DRUG MODELING SOFTWARE MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 90
TABLE 21 MIDDLE EAST & AFRICA GRAPHICAL MOLECULAR MODELING IN DRUG MODELING SOFTWARE MARKET, BY REGION, 2021-2030 (USD MILLION) 91
TABLE 22 MIDDLE EAST & AFRICA GENE SEQUENCE ANALYSIS IN DRUG MODELING SOFTWARE MARKET, BY REGION, 2021-2030 (USD MILLION) 92
TABLE 23 MIDDLE EAST & AFRICA PROTEIN MODELING IN DRUG MODELING SOFTWARE MARKET, BY REGION, 2021-2030 (USD MILLION) 93
TABLE 24 MIDDLE EAST & AFRICA MODELING CRYSTAL STRUCTURES IN DRUG MODELING SOFTWARE MARKET, BY REGION, 2021-2030 (USD MILLION) 94
TABLE 25 MIDDLE EAST & AFRICA CHEMINFORMATICS IN DRUG MODELING SOFTWARE MARKET, BY REGION, 2021-2030 (USD MILLION) 94
TABLE 26 MIDDLE EAST & AFRICA HIGH THROUGHPUT VIRTUAL SCREENING IN DRUG MODELING SOFTWARE MARKET, BY REGION, 2021-2030 (USD MILLION) 95
TABLE 27 MIDDLE EAST & AFRICA GAS & SOLUTION PHASE REACTION IN DRUG MODELING SOFTWARE MARKET, BY REGION, 2021-2030 (USD MILLION) 96
TABLE 28 MIDDLE EAST & AFRICA MEDICAL IMAGING IN DRUG MODELING SOFTWARE MARKET, BY REGION, 2021-2030 (USD MILLION) 97
TABLE 29 MIDDLE EAST & AFRICA OTHERS IN DRUG MODELING SOFTWARE MARKET, BY REGION, 2021-2030 (USD MILLION) 97
TABLE 30 MIDDLE EAST & AFRICA DRUG MODELING SOFTWARE MARKET, BY PURCHASING MODEL, 2021-2030 (USD MILLION) 101
TABLE 31 MIDDLE EAST & AFRICA SUBSCRIPTION BASED IN DRUG MODELING SOFTWARE MARKET, BY REGION, 2021-2030 (USD MILLION) 102
TABLE 32 MIDDLE EAST & AFRICA SUBSCRIPTION BASED IN DRUG MODELING SOFTWARE MARKET, BY PURCHASING MODEL, 2021-2030 (USD MILLION) 102
TABLE 33 MIDDLE EAST & AFRICA ONE-TIME LICENSE IN DRUG MODELING SOFTWARE MARKET, BY REGION, 2021-2030 (USD MILLION) 103
TABLE 34 MIDDLE EAST & AFRICA ONE-TIME LICENSE IN DRUG MODELING SOFTWARE MARKET, BY PURCHASING MODEL, 2021-2030 (USD MILLION) 104
TABLE 35 MIDDLE EAST & AFRICA DRUG MODELING SOFTWARE MARKET, BY END USER, 2021-2030 (USD MILLION) 108
TABLE 36 MIDDLE EAST & AFRICA PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES IN DRUG MODELING SOFTWARE MARKET, BY REGION, 2021-2030 (USD MILLION) 109
TABLE 37 MIDDLE EAST & AFRICA PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES IN DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 109
TABLE 38 MIDDLE EAST & AFRICA CONTRACT RESEARCH ORGANIZATIONS IN DRUG MODELING SOFTWARE MARKET, BY REGION, 2021-2030 (USD MILLION) 110
TABLE 39 MIDDLE EAST & AFRICA CONTRACT RESEARCH ORGANIZATIONS IN DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 111
TABLE 40 MIDDLE EAST & AFRICA RESEARCH INSTITUTES IN DRUG MODELING SOFTWARE MARKET, BY REGION, 2021-2030 (USD MILLION) 112
TABLE 41 MIDDLE EAST & AFRICA RESEARCH INSTITUTES IN DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 112
TABLE 42 MIDDLE EAST & AFRICA REGULATORY AUTHORITIES IN DRUG MODELING SOFTWARE MARKET, BY REGION, 2021-2030 (USD MILLION) 113
TABLE 43 MIDDLE EAST & AFRICA REGULATORY AUTHORITIES IN DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 113
TABLE 44 MIDDLE EAST & AFRICA OTHERS IN DRUG MODELING SOFTWARE MARKET, BY REGION, 2021-2030 (USD MILLION) 114
TABLE 45 MIDDLE EAST & AFRICA OTHERS IN DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 114
TABLE 46 MIDDLE EAST AND AFRICA DRUG MODELING SOFTWARE MARKET, BY COUNTRY, 2021-2030 (USD MILLION) 122
TABLE 47 MIDDLE EAST AND AFRICA DRUG MODELING SOFTWARE MARKET, BY COMPONENTS, 2021-2030 (USD MILLION) 122
TABLE 48 MIDDLE EAST AND AFRICA SOFTWARE IN DRUG MODELING SOFTWARE MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 122
TABLE 49 MIDDLE EAST AND AFRICA SOFTWARE IN DRUG MODELING SOFTWARE MARKET, BY TYPE, 2021-2030 (USD MILLION) 122
TABLE 50 MIDDLE EAST AND AFRICA SERVICES IN DRUG MODELING SOFTWARE MARKET, BY TYPE, 2021-2030 (USD MILLION) 123
TABLE 51 MIDDLE EAST AND AFRICA PROFESSIONAL SERVICES IN DRUG MODELING SOFTWARE MARKET, BY TYPE, 2021-2030 (USD MILLION) 123
TABLE 52 MIDDLE EAST AND AFRICA DRUG MODELING SOFTWARE MARKET, BY OPERATING SYSTEM, 2021-2030 (USD MILLION) 123
TABLE 53 MIDDLE EAST AND AFRICA DRUG MODELING SOFTWARE MARKET, BY DEPLOYMENT MODE, 2021-2030 (USD MILLION) 123
TABLE 54 MIDDLE EAST AND AFRICA DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 124
TABLE 55 MIDDLE EAST AND AFRICA DRUG MODELING SOFTWARE MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 124
TABLE 56 MIDDLE EAST AND AFRICA DRUG MODELING SOFTWARE MARKET, BY PURCHASING MODEL, 2021-2030 (USD MILLION) 124
TABLE 57 MIDDLE EAST AND AFRICA SUBSCRIPTION BASED IN DRUG MODELING SOFTWARE MARKET, BY PURCHASING MODEL, 2021-2030 (USD MILLION) 125
TABLE 58 MIDDLE EAST AND AFRICA ONE-TIME LICENSE IN DRUG MODELING SOFTWARE MARKET, BY PURCHASING MODEL, 2021-2030 (USD MILLION) 125
TABLE 59 MIDDLE EAST AND AFRICA DRUG MODELING SOFTWARE MARKET, BY END USER, 2021-2030 (USD MILLION) 125
TABLE 60 MIDDLE EAST AND AFRICA PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES IN DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 125
TABLE 61 MIDDLE EAST AND AFRICA CONTRACT RESEARCH ORGANIZATIONS IN DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 126
TABLE 62 MIDDLE EAST AND AFRICA RESEARCH INSTITUTES IN DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 126
TABLE 63 MIDDLE EAST AND AFRICA REGULATORY AUTHORITIES IN DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 126
TABLE 64 MIDDLE EAST AND AFRICA OTHERS IN DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 126
TABLE 65 SOUTH AFRICA DRUG MODELING SOFTWARE MARKET, BY COMPONENTS, 2021-2030 (USD MILLION) 127
TABLE 66 SOUTH AFRICA SOFTWARE IN DRUG MODELING SOFTWARE MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 127
TABLE 67 SOUTH AFRICA SOFTWARE IN DRUG MODELING SOFTWARE MARKET, BY TYPE, 2021-2030 (USD MILLION) 127
TABLE 68 SOUTH AFRICA SERVICES IN DRUG MODELING SOFTWARE MARKET, BY TYPE, 2021-2030 (USD MILLION) 127
TABLE 69 SOUTH AFRICA PROFESSIONAL SERVICES IN DRUG MODELING SOFTWARE MARKET, BY TYPE, 2021-2030 (USD MILLION) 128
TABLE 70 SOUTH AFRICA DRUG MODELING SOFTWARE MARKET, BY OPERATING SYSTEM, 2021-2030 (USD MILLION) 128
TABLE 71 SOUTH AFRICA DRUG MODELING SOFTWARE MARKET, BY DEPLOYMENT MODE, 2021-2030 (USD MILLION) 128
TABLE 72 SOUTH AFRICA DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 128
TABLE 73 SOUTH AFRICA DRUG MODELING SOFTWARE MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 129
TABLE 74 SOUTH AFRICA DRUG MODELING SOFTWARE MARKET, BY PURCHASING MODEL, 2021-2030 (USD MILLION) 129
TABLE 75 SOUTH AFRICA SUBSCRIPTION BASED IN DRUG MODELING SOFTWARE MARKET, BY PURCHASING MODEL, 2021-2030 (USD MILLION) 129
TABLE 76 SOUTH AFRICA ONE-TIME LICENSE IN DRUG MODELING SOFTWARE MARKET, BY PURCHASING MODEL, 2021-2030 (USD MILLION) 130
TABLE 77 SOUTH AFRICA DRUG MODELING SOFTWARE MARKET, BY END USER, 2021-2030 (USD MILLION) 130
TABLE 78 SOUTH AFRICA PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES IN DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 130
TABLE 79 SOUTH AFRICA CONTRACT RESEARCH ORGANIZATIONS IN DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 131
TABLE 80 SOUTH AFRICA RESEARCH INSTITUTES IN DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 131
TABLE 81 SOUTH AFRICA REGULATORY AUTHORITIES IN DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 131
TABLE 82 SOUTH AFRICA OTHERS IN DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 131
TABLE 83 SAUDI ARABIA DRUG MODELING SOFTWARE MARKET, BY COMPONENTS, 2021-2030 (USD MILLION) 132
TABLE 84 SAUDI ARABIA SOFTWARE IN DRUG MODELING SOFTWARE MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 132
TABLE 85 SAUDI ARABIA SOFTWARE IN DRUG MODELING SOFTWARE MARKET, BY TYPE, 2021-2030 (USD MILLION) 132
TABLE 86 SAUDI ARABIA SERVICES IN DRUG MODELING SOFTWARE MARKET, BY TYPE, 2021-2030 (USD MILLION) 132
TABLE 87 SAUDI ARABIA PROFESSIONAL SERVICES IN DRUG MODELING SOFTWARE MARKET, BY TYPE, 2021-2030 (USD MILLION) 133
TABLE 88 SAUDI ARABIA DRUG MODELING SOFTWARE MARKET, BY OPERATING SYSTEM, 2021-2030 (USD MILLION) 133
TABLE 89 SAUDI ARABIA DRUG MODELING SOFTWARE MARKET, BY DEPLOYMENT MODE, 2021-2030 (USD MILLION) 133
TABLE 90 SAUDI ARABIA DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 133
TABLE 91 SAUDI ARABIA DRUG MODELING SOFTWARE MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 134
TABLE 92 SAUDI ARABIA DRUG MODELING SOFTWARE MARKET, BY PURCHASING MODEL, 2021-2030 (USD MILLION) 134
TABLE 93 SAUDI ARABIA SUBSCRIPTION BASED IN DRUG MODELING SOFTWARE MARKET, BY PURCHASING MODEL, 2021-2030 (USD MILLION) 134
TABLE 94 SAUDI ARABIA ONE-TIME LICENSE IN DRUG MODELING SOFTWARE MARKET, BY PURCHASING MODEL, 2021-2030 (USD MILLION) 135
TABLE 95 SAUDI ARABIA DRUG MODELING SOFTWARE MARKET, BY END USER, 2021-2030 (USD MILLION) 135
TABLE 96 SAUDI ARABIA PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES IN DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 135
TABLE 97 SAUDI ARABIA CONTRACT RESEARCH ORGANIZATIONS IN DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 136
TABLE 98 SAUDI ARABIA RESEARCH INSTITUTES IN DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 136
TABLE 99 SAUDI ARABIA REGULATORY AUTHORITIES IN DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 136
TABLE 100 SAUDI ARABIA OTHERS IN DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 136
TABLE 101 U.A.E. DRUG MODELING SOFTWARE MARKET, BY COMPONENTS, 2021-2030 (USD MILLION) 137
TABLE 102 U.A.E. SOFTWARE IN DRUG MODELING SOFTWARE MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 137
TABLE 103 U.A.E. SOFTWARE IN DRUG MODELING SOFTWARE MARKET, BY TYPE, 2021-2030 (USD MILLION) 137
TABLE 104 U.A.E. SERVICES IN DRUG MODELING SOFTWARE MARKET, BY TYPE, 2021-2030 (USD MILLION) 137
TABLE 105 U.A.E. PROFESSIONAL SERVICES IN DRUG MODELING SOFTWARE MARKET, BY TYPE, 2021-2030 (USD MILLION) 138
TABLE 106 U.A.E. DRUG MODELING SOFTWARE MARKET, BY OPERATING SYSTEM, 2021-2030 (USD MILLION) 138
TABLE 107 U.A.E. DRUG MODELING SOFTWARE MARKET, BY DEPLOYMENT MODE, 2021-2030 (USD MILLION) 138
TABLE 108 U.A.E. DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 138
TABLE 109 U.A.E. DRUG MODELING SOFTWARE MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 139
TABLE 110 U.A.E. DRUG MODELING SOFTWARE MARKET, BY PURCHASING MODEL, 2021-2030 (USD MILLION) 139
TABLE 111 U.A.E. SUBSCRIPTION BASED IN DRUG MODELING SOFTWARE MARKET, BY PURCHASING MODEL, 2021-2030 (USD MILLION) 139
TABLE 112 U.A.E. ONE-TIME LICENSE IN DRUG MODELING SOFTWARE MARKET, BY PURCHASING MODEL, 2021-2030 (USD MILLION) 140
TABLE 113 U.A.E. DRUG MODELING SOFTWARE MARKET, BY END USER, 2021-2030 (USD MILLION) 140
TABLE 114 U.A.E. PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES IN DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 140
TABLE 115 U.A.E. CONTRACT RESEARCH ORGANIZATIONS IN DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 140
TABLE 116 U.A.E. RESEARCH INSTITUTES IN DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 141
TABLE 117 U.A.E. REGULATORY AUTHORITIES IN DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 141
TABLE 118 U.A.E. OTHERS IN DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 141
TABLE 119 EGYPT DRUG MODELING SOFTWARE MARKET, BY COMPONENTS, 2021-2030 (USD MILLION) 142
TABLE 120 EGYPT SOFTWARE IN DRUG MODELING SOFTWARE MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 142
TABLE 121 EGYPT SOFTWARE IN DRUG MODELING SOFTWARE MARKET, BY TYPE, 2021-2030 (USD MILLION) 142
TABLE 122 EGYPT SERVICES IN DRUG MODELING SOFTWARE MARKET, BY TYPE, 2021-2030 (USD MILLION) 142
TABLE 123 EGYPT PROFESSIONAL SERVICES IN DRUG MODELING SOFTWARE MARKET, BY TYPE, 2021-2030 (USD MILLION) 143
TABLE 124 EGYPT DRUG MODELING SOFTWARE MARKET, BY OPERATING SYSTEM, 2021-2030 (USD MILLION) 143
TABLE 125 EGYPT DRUG MODELING SOFTWARE MARKET, BY DEPLOYMENT MODE, 2021-2030 (USD MILLION) 143
TABLE 126 EGYPT DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 143
TABLE 127 EGYPT DRUG MODELING SOFTWARE MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 144
TABLE 128 EGYPT DRUG MODELING SOFTWARE MARKET, BY PURCHASING MODEL, 2021-2030 (USD MILLION) 144
TABLE 129 EGYPT SUBSCRIPTION BASED IN DRUG MODELING SOFTWARE MARKET, BY PURCHASING MODEL, 2021-2030 (USD MILLION) 144
TABLE 130 EGYPT ONE-TIME LICENSE IN DRUG MODELING SOFTWARE MARKET, BY PURCHASING MODEL, 2021-2030 (USD MILLION) 145
TABLE 131 EGYPT DRUG MODELING SOFTWARE MARKET, BY END USER, 2021-2030 (USD MILLION) 145
TABLE 132 EGYPT PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES IN DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 145
TABLE 133 EGYPT CONTRACT RESEARCH ORGANIZATIONS IN DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 145
TABLE 134 EGYPT RESEARCH INSTITUTES IN DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 146
TABLE 135 EGYPT REGULATORY AUTHORITIES IN DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 146
TABLE 136 EGYPT OTHERS IN DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 146
TABLE 137 ISRAEL DRUG MODELING SOFTWARE MARKET, BY COMPONENTS, 2021-2030 (USD MILLION) 147
TABLE 138 ISRAEL SOFTWARE IN DRUG MODELING SOFTWARE MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 147
TABLE 139 ISRAEL SOFTWARE IN DRUG MODELING SOFTWARE MARKET, BY TYPE, 2021-2030 (USD MILLION) 147
TABLE 140 ISRAEL SERVICES IN DRUG MODELING SOFTWARE MARKET, BY TYPE, 2021-2030 (USD MILLION) 147
TABLE 141 ISRAEL PROFESSIONAL SERVICES IN DRUG MODELING SOFTWARE MARKET, BY TYPE, 2021-2030 (USD MILLION) 148
TABLE 142 ISRAEL DRUG MODELING SOFTWARE MARKET, BY OPERATING SYSTEM, 2021-2030 (USD MILLION) 148
TABLE 143 ISRAEL DRUG MODELING SOFTWARE MARKET, BY DEPLOYMENT MODE, 2021-2030 (USD MILLION) 148
TABLE 144 ISRAEL DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 148
TABLE 145 ISRAEL DRUG MODELING SOFTWARE MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 149
TABLE 146 ISRAEL DRUG MODELING SOFTWARE MARKET, BY PURCHASING MODEL, 2021-2030 (USD MILLION) 149
TABLE 147 ISRAEL SUBSCRIPTION BASED IN DRUG MODELING SOFTWARE MARKET, BY PURCHASING MODEL, 2021-2030 (USD MILLION) 149
TABLE 148 ISRAEL ONE-TIME LICENSE IN DRUG MODELING SOFTWARE MARKET, BY PURCHASING MODEL, 2021-2030 (USD MILLION) 150
TABLE 149 ISRAEL DRUG MODELING SOFTWARE MARKET, BY END USER, 2021-2030 (USD MILLION) 150
TABLE 150 ISRAEL PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES IN DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 150
TABLE 151 ISRAEL CONTRACT RESEARCH ORGANIZATIONS IN DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 150
TABLE 152 ISRAEL RESEARCH INSTITUTES IN DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 151
TABLE 153 ISRAEL REGULATORY AUTHORITIES IN DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 151
TABLE 154 ISRAEL OTHERS IN DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 151
TABLE 155 OMAN DRUG MODELING SOFTWARE MARKET, BY COMPONENTS, 2021-2030 (USD MILLION) 152
TABLE 156 OMAN SOFTWARE IN DRUG MODELING SOFTWARE MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 152
TABLE 157 OMAN SOFTWARE IN DRUG MODELING SOFTWARE MARKET, BY TYPE, 2021-2030 (USD MILLION) 152
TABLE 158 OMAN SERVICES IN DRUG MODELING SOFTWARE MARKET, BY TYPE, 2021-2030 (USD MILLION) 152
TABLE 159 OMAN PROFESSIONAL SERVICES IN DRUG MODELING SOFTWARE MARKET, BY TYPE, 2021-2030 (USD MILLION) 153
TABLE 160 OMAN DRUG MODELING SOFTWARE MARKET, BY OPERATING SYSTEM, 2021-2030 (USD MILLION) 153
TABLE 161 OMAN DRUG MODELING SOFTWARE MARKET, BY DEPLOYMENT MODE, 2021-2030 (USD MILLION) 153
TABLE 162 OMAN DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 153
TABLE 163 OMAN DRUG MODELING SOFTWARE MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 154
TABLE 164 OMAN DRUG MODELING SOFTWARE MARKET, BY PURCHASING MODEL, 2021-2030 (USD MILLION) 154

TABLE 165 OMAN SUBSCRIPTION BASED IN DRUG MODELING SOFTWARE MARKET, BY PURCHASING MODEL, 2021-2030 (USD MILLION) 154
TABLE 166 OMAN ONE-TIME LICENSE IN DRUG MODELING SOFTWARE MARKET, BY PURCHASING MODEL, 2021-2030 (USD MILLION) 155
TABLE 167 OMAN DRUG MODELING SOFTWARE MARKET, BY END USER, 2021-2030 (USD MILLION) 155
TABLE 168 OMAN PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES IN DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 155
TABLE 169 OMAN CONTRACT RESEARCH ORGANIZATIONS IN DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 155
TABLE 170 OMAN RESEARCH INSTITUTES IN DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 156
TABLE 171 OMAN REGULATORY AUTHORITIES IN DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 156
TABLE 172 OMAN OTHERS IN DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 156
TABLE 173 BAHRAIN DRUG MODELING SOFTWARE MARKET, BY COMPONENTS, 2021-2030 (USD MILLION) 157
TABLE 174 BAHRAIN SOFTWARE IN DRUG MODELING SOFTWARE MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 157
TABLE 175 BAHRAIN SOFTWARE IN DRUG MODELING SOFTWARE MARKET, BY TYPE, 2021-2030 (USD MILLION) 157
TABLE 176 BAHRAIN SERVICES IN DRUG MODELING SOFTWARE MARKET, BY TYPE, 2021-2030 (USD MILLION) 157
TABLE 177 BAHRAIN PROFESSIONAL SERVICES IN DRUG MODELING SOFTWARE MARKET, BY TYPE, 2021-2030 (USD MILLION) 158
TABLE 178 BAHRAIN DRUG MODELING SOFTWARE MARKET, BY OPERATING SYSTEM, 2021-2030 (USD MILLION) 158
TABLE 179 BAHRAIN DRUG MODELING SOFTWARE MARKET, BY DEPLOYMENT MODE, 2021-2030 (USD MILLION) 158
TABLE 180 BAHRAIN DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 158
TABLE 181 BAHRAIN DRUG MODELING SOFTWARE MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 159
TABLE 182 BAHRAIN DRUG MODELING SOFTWARE MARKET, BY PURCHASING MODEL, 2021-2030 (USD MILLION) 159
TABLE 183 BAHRAIN SUBSCRIPTION BASED IN DRUG MODELING SOFTWARE MARKET, BY PURCHASING MODEL, 2021-2030 (USD MILLION) 159
TABLE 184 BAHRAIN ONE-TIME LICENSE IN DRUG MODELING SOFTWARE MARKET, BY PURCHASING MODEL, 2021-2030 (USD MILLION) 160
TABLE 185 BAHRAIN DRUG MODELING SOFTWARE MARKET, BY END USER, 2021-2030 (USD MILLION) 160
TABLE 186 BAHRAIN PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES IN DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 160
TABLE 187 BAHRAIN CONTRACT RESEARCH ORGANIZATIONS IN DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 160
TABLE 188 BAHRAIN RESEARCH INSTITUTES IN DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 161
TABLE 189 BAHRAIN REGULATORY AUTHORITIES IN DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 161
TABLE 190 BAHRAIN OTHERS IN DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 161
TABLE 191 KUWAIT DRUG MODELING SOFTWARE MARKET, BY COMPONENTS, 2021-2030 (USD MILLION) 162
TABLE 192 KUWAIT SOFTWARE IN DRUG MODELING SOFTWARE MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 162
TABLE 193 KUWAIT SOFTWARE IN DRUG MODELING SOFTWARE MARKET, BY TYPE, 2021-2030 (USD MILLION) 162
TABLE 194 KUWAIT SERVICES IN DRUG MODELING SOFTWARE MARKET, BY TYPE, 2021-2030 (USD MILLION) 162
TABLE 195 KUWAIT PROFESSIONAL SERVICES IN DRUG MODELING SOFTWARE MARKET, BY TYPE, 2021-2030 (USD MILLION) 163
TABLE 196 KUWAIT DRUG MODELING SOFTWARE MARKET, BY OPERATING SYSTEM, 2021-2030 (USD MILLION) 163
TABLE 197 KUWAIT DRUG MODELING SOFTWARE MARKET, BY DEPLOYMENT MODE, 2021-2030 (USD MILLION) 163
TABLE 198 KUWAIT DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 163
TABLE 199 KUWAIT DRUG MODELING SOFTWARE MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 164
TABLE 200 KUWAIT DRUG MODELING SOFTWARE MARKET, BY PURCHASING MODEL, 2021-2030 (USD MILLION) 164
TABLE 201 KUWAIT SUBSCRIPTION BASED IN DRUG MODELING SOFTWARE MARKET, BY PURCHASING MODEL, 2021-2030 (USD MILLION) 164
TABLE 202 KUWAIT ONE-TIME LICENSE IN DRUG MODELING SOFTWARE MARKET, BY PURCHASING MODEL, 2021-2030 (USD MILLION) 165
TABLE 203 KUWAIT DRUG MODELING SOFTWARE MARKET, BY END USER, 2021-2030 (USD MILLION) 165
TABLE 204 KUWAIT PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES IN DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 165
TABLE 205 KUWAIT CONTRACT RESEARCH ORGANIZATIONS IN DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 165
TABLE 206 KUWAIT RESEARCH INSTITUTES IN DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 166
TABLE 207 KUWAIT REGULATORY AUTHORITIES IN DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 166
TABLE 208 KUWAIT OTHERS IN DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 166
TABLE 209 QATAR DRUG MODELING SOFTWARE MARKET, BY COMPONENTS, 2021-2030 (USD MILLION) 167
TABLE 210 QATAR SOFTWARE IN DRUG MODELING SOFTWARE MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 167
TABLE 211 QATAR SOFTWARE IN DRUG MODELING SOFTWARE MARKET, BY TYPE, 2021-2030 (USD MILLION) 167
TABLE 212 QATAR SERVICES IN DRUG MODELING SOFTWARE MARKET, BY TYPE, 2021-2030 (USD MILLION) 167
TABLE 213 QATAR PROFESSIONAL SERVICES IN DRUG MODELING SOFTWARE MARKET, BY TYPE, 2021-2030 (USD MILLION) 168
TABLE 214 QATAR DRUG MODELING SOFTWARE MARKET, BY OPERATING SYSTEM, 2021-2030 (USD MILLION) 168
TABLE 215 QATAR DRUG MODELING SOFTWARE MARKET, BY DEPLOYMENT MODE, 2021-2030 (USD MILLION) 168
TABLE 216 QATAR DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 168
TABLE 217 QATAR DRUG MODELING SOFTWARE MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 169
TABLE 218 QATAR DRUG MODELING SOFTWARE MARKET, BY PURCHASING MODEL, 2021-2030 (USD MILLION) 169
TABLE 219 QATAR SUBSCRIPTION BASED IN DRUG MODELING SOFTWARE MARKET, BY PURCHASING MODEL, 2021-2030 (USD MILLION) 169
TABLE 220 QATAR ONE-TIME LICENSE IN DRUG MODELING SOFTWARE MARKET, BY PURCHASING MODEL, 2021-2030 (USD MILLION) 170
TABLE 221 QATAR DRUG MODELING SOFTWARE MARKET, BY END USER, 2021-2030 (USD MILLION) 170
TABLE 222 QATAR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES IN DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 170
TABLE 223 QATAR CONTRACT RESEARCH ORGANIZATIONS IN DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 170
TABLE 224 QATAR RESEARCH INSTITUTES IN DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 171
TABLE 225 QATAR REGULATORY AUTHORITIES IN DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 171
TABLE 226 QATAR OTHERS IN DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 171
TABLE 227 REST OF MIDDLE EAST AND AFRICA DRUG MODELING SOFTWARE MARKET, BY COMPONENTS, 2021-2030 (USD MILLION) 172

LIST OF FIGURES

FIGURE 1 MIDDLE EAST & AFRICA DRUG MODELING SOFTWARE MARKET: SEGMENTATION 28
FIGURE 2 MIDDLE EAST & AFRICA DRUG MODELING SOFTWARE MARKET: DATA TRIANGULATION 31
FIGURE 3 MIDDLE EAST & AFRICA DRUG MODELING SOFTWARE MARKET: DROC ANALYSIS 32
FIGURE 4 MIDDLE EAST & AFRICA DRUG MODELING SOFTWARE MARKET: MIDDLE EAST & AFRICA VS. REGIONAL MARKET ANALYSIS 33
FIGURE 5 MIDDLE EAST & AFRICA DRUG MODELING SOFTWARE MARKET: COMPANY RESEARCH ANALYSIS 33
FIGURE 6 MIDDLE EAST & AFRICA DRUG MODELING SOFTWARE MARKET: INTERVIEW DEMOGRAPHICS 34
FIGURE 7 MIDDLE EAST & AFRICA DRUG MODELING SOFTWARE MARKET: MULTIVARIATE MODELING 35
FIGURE 8 MIDDLE EAST & AFRICA DRUG MODELING SOFTWARE MARKET: DBMR MARKET POSITION GRID 36
FIGURE 9 MIDDLE EAST & AFRICA DRUG MODELING SOFTWARE MARKET: VENDOR SHARE ANALYSIS 37
FIGURE 10 MIDDLE EAST & AFRICA DRUG MODELING SOFTWARE MARKET: MARKET APPLICATION COVERAGE GRID 38
FIGURE 11 MIDDLE EAST & AFRICA DRUG MODELING SOFTWARE MARKET: SEGMENTATION 42
FIGURE 12 RISING DRUG DISCOVERY AND DEVELOPMENT ACTIVITIES, RISING DEMAND FOR NOVEL THERAPIES, AND PRECISION MEDICINE AND INTERVENTION OF AI IN DRUG MODELLING ARE ARE EXPECTED TO DRIVE THE MIDDLE EAST & AFRICA DRUG MODELING SOFTWARE MARKET GROWTH IN THE FORECAST PERIOD FROM 2023 TO 2030 43
FIGURE 13 SOFTWARE SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE MIDDLE EAST & AFRICA DRUG MODELING SOFTWARE MARKET IN 2023 & 2030 43
FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE MIDDLE EAST & AFRICA DRUG MODELING SOFTWARE MARKET 50
FIGURE 15 MIDDLE EAST & AFRICA DRUG MODELING SOFTWARE MARKET: BY COMPONENTS, 2022 60
FIGURE 16 MIDDLE EAST & AFRICA DRUG MODELING SOFTWARE MARKET: BY COMPONENTS, 2023-2030 (USD MILLION) 61
FIGURE 17 MIDDLE EAST & AFRICA DRUG MODELING SOFTWARE MARKET: BY COMPONENTS, CAGR (2023-2030) 61
FIGURE 18 MIDDLE EAST & AFRICA DRUG MODELING SOFTWARE MARKET: BY COMPONENTS, LIFELINE CURVE 62
FIGURE 19 MIDDLE EAST & AFRICA DRUG MODELING SOFTWARE MARKET: BY OPERATING SYSTEM, 2022 68
FIGURE 20 MIDDLE EAST & AFRICA DRUG MODELING SOFTWARE MARKET: BY OPERATING SYSTEM, 2023-2030 (USD MILLION) 69
FIGURE 21 MIDDLE EAST & AFRICA DRUG MODELING SOFTWARE MARKET: BY OPERATING SYSTEM, CAGR (2023-2030) 69
FIGURE 22 MIDDLE EAST & AFRICA DRUG MODELING SOFTWARE MARKET: BY OPERATING SYSTEM, LIFELINE CURVE 70
FIGURE 23 MIDDLE EAST & AFRICA DRUG MODELING SOFTWARE MARKET: BY DEPLOYMENT MODE, 2022 75
FIGURE 24 MIDDLE EAST & AFRICA DRUG MODELING SOFTWARE MARKET: BY DEPLOYMENT MODE, 2023-2030 (USD MILLION) 76
FIGURE 25 MIDDLE EAST & AFRICA DRUG MODELING SOFTWARE MARKET: BY DEPLOYMENT MODE, CAGR (2023-2030) 76
FIGURE 26 MIDDLE EAST & AFRICA DRUG MODELING SOFTWARE MARKET: BY DEPLOYMENT MODE, LIFELINE CURVE 77
FIGURE 27 MIDDLE EAST & AFRICA DRUG MODELING SOFTWARE MARKET: BY ENTERPRISE SIZE, 2022 81
FIGURE 28 MIDDLE EAST & AFRICA DRUG MODELING SOFTWARE MARKET: BY ENTERPRISE SIZE, 2023-2030 (USD MILLION) 82
FIGURE 29 MIDDLE EAST & AFRICA DRUG MODELING SOFTWARE MARKET: BY ENTERPRISE SIZE, CAGR (2023-2030) 82
FIGURE 30 MIDDLE EAST & AFRICA DRUG MODELING SOFTWARE MARKET: BY ENTERPRISE SIZE, LIFELINE CURVE 83
FIGURE 31 MIDDLE EAST & AFRICA DRUG MODELING SOFTWARE MARKET: BY APPLICATION, 2022 87
FIGURE 32 MIDDLE EAST & AFRICA DRUG MODELING SOFTWARE MARKET: BY APPLICATION, 2023-2030 (USD MILLION) 88
FIGURE 33 MIDDLE EAST & AFRICA DRUG MODELING SOFTWARE MARKET: BY APPLICATION, CAGR (2023-2030) 88
FIGURE 34 MIDDLE EAST & AFRICA DRUG MODELING SOFTWARE MARKET: BY APPLICATION, LIFELINE CURVE 89
FIGURE 35 MIDDLE EAST & AFRICA DRUG MODELING SOFTWARE MARKET: BY PURCHASING MODEL, 2022 98
FIGURE 36 MIDDLE EAST & AFRICA DRUG MODELING SOFTWARE MARKET: BY PURCHASING MODEL, 2023-2030 (USD MILLION) 99
FIGURE 37 MIDDLE EAST & AFRICA DRUG MODELING SOFTWARE MARKET: BY PURCHASING MODEL, CAGR (2023-2030) 99
FIGURE 38 MIDDLE EAST & AFRICA DRUG MODELING SOFTWARE MARKET: BY PURCHASING MODEL, LIFELINE CURVE 100
FIGURE 39 MIDDLE EAST & AFRICA DRUG MODELING SOFTWARE MARKET: BY END USER, 2022 105
FIGURE 40 MIDDLE EAST & AFRICA DRUG MODELING SOFTWARE MARKET: BY END USER, 2023-2030 (USD MILLION) 106
FIGURE 41 MIDDLE EAST & AFRICA DRUG MODELING SOFTWARE MARKET: BY END USER, CAGR (2023-2030) 106
FIGURE 42 MIDDLE EAST & AFRICA DRUG MODELING SOFTWARE MARKET: BY END USER, LIFELINE CURVE 107
FIGURE 43 MIDDLE EAST AND AFRICA DRUG MODELING SOFTWARE MARKET: SNAPSHOT (2022) 117
FIGURE 44 MIDDLE EAST AND AFRICA DRUG MODELING SOFTWARE MARKET: BY COUNTRY (2022) 119
FIGURE 45 MIDDLE EAST AND AFRICA DRUG MODELING SOFTWARE MARKET: BY COUNTRY (2023 & 2030) 119
FIGURE 46 MIDDLE EAST AND AFRICA DRUG MODELING SOFTWARE MARKET: BY COUNTRY (2022 & 2030) 120
FIGURE 47 MIDDLE EAST AND AFRICA DRUG MODELING SOFTWARE MARKET: BY COMPONENTS (2023-2030) 120
FIGURE 48 MIDDLE EAST & AFRICA DRUG MODELING SOFTWARE MARKET: COMPANY SHARE 2022 (%) 172